Navigation Links
Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible

For everyone doing or reading a paper about microarray-based experiments, reproductibility, especially inter-lab, is the #1 concern. Can I trust these results? If I redo the same experiment in one month, will I be able to compare both? The NIH recently demonstrated that microarrays experiments performed in different labs "have a high degree of reproducibility, as long as standardized protocols are carefully followed". Good news for the scientific community (and the microarrays producing companies)! A study funded by the National Cancer Institute, part of the National Institutes of Health, shows for the first time that microarray data generated in different laboratories can produce highly comparable results. For this comparison study, appearing in the Jan. 15, 2005, Clinical Cancer Research*, four separate laboratories analyzed gene expression (whether genes are turned on or off) for the same set of human tumor tissues. Overall, the expression profiles of portions of individual samples were highly comparable, and the experimental correlation between separate labs was only slightly lower than correlation of duplicated experiments within the same labs.

“This study is a key first step in moving gene expression data from small-scale bench science into large-scale clinical evaluation,?said James Jacobson, Ph.D., chief of NCI’s Diagnostic Biomarkers and Technology Branch. Gene expression microarrays have been used in numerous applications, including identifying novel genes associated with certain cancers, classifying tumors, and predicting patient outcome. So far, though, microarray studies have been performed by individual institutions. Evaluation of the potential clinical use of microarrays may require larger studies carried out in multiple locations and would neces sitate that microarray data produced in different laboratories be combined for analysis. Even if all procedures and equipment were the same, small differences between labs, such as in handling the tissue samples, extracting the RNA, or scanning the microarrays, could result in different profiles. To test the feasibility of multi-lab microarray studies, the NCI’s Director’s Challenge program set up this preliminary study to compare results between labs. Twelve different tumor tissues, five cancer cell lines, and five purified RNA samples were prepared, blinded, and randomized for analysis in four laboratories: University of Michigan Medical School, Ann Arbor, Mich.; Dana Farber Cancer Institute/Whitehead Institute, Boston, Mass.; Memorial Sloan-Kettering Cancer Center, New York, N.Y.; and H. Lee Moffitt Cancer Center, Tampa, Fla. All five cell lines and RNA samples were derived from lung carcinomas, while the tissue samples were derived from multiple normal and cancerous tissues. The labs followed a common protocol for all steps of sample preparation and microarray analysis and the resulting gene expression profiles were analyzed and compared. Sample correlation within each lab was extremely high; microarray data from the RNA samples had the highest correlation values, followed by the cell lines, and then finally the tissue samples. This was not surprising, as RNA required the fewest steps of preparation, while tissues required the most. The between-lab correlation values decreased slightly for all samples, but in all cases expression profiles of similar samples could be accurately grouped together. The researchers also examined variations of individual gene measurements to help determine causes of variability, and they found that laboratory practices comprised the smallest source of variation in these studies. Measurement errors common to all labs were the next most common contributor, and biological differences in different samples were the largest source of variat ion. “This study indicates that microarrays have a high degree of reproducibility, as long as standardized protocols are carefully followed,?said Jacobson. These promising results will allow this same research group to proceed with a larger gene expression analysis of 600 stage I lung adenocarcinomas, with the hopes of confirming a previous association between gene expression profiles and patient outcome. This project is also an example of NCI interest in developing public/private partnerships. Affymetrix, of Santa Clara, Calif., contributed part of the arrays for this comparison study and provided technical assistance to the four sites carrying out the study. Ardais Corporation, Lexington, Mass., provided the RNA samples used for analysis.
'"/>

Source:NIH


Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
3. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
4. Study Links Ebola Outbreaks To Animal Carcasses
5. Breakthrough Microarray-based Technology for the Study of Cancer
6. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
7. Study finds more than one-third of human genome regulated by RNA
8. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
9. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
10. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works
11. Study: Soap And Water Work Best In Ridding Hands Of Disease Viruses

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... A new study published ... frozen and fresh in vitro fertilization (IVF) transfer cycles. The multi-center ... success. , After comparing the results from the fresh and frozen transfer cohorts, ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
(Date:10/10/2017)... Oct. 10, 2017 International research firm Parks Associates ... speak at the TMA 2017 Annual Meeting , October 11 in ... the residential home security market and how smart safety and security products ... Parks Associates: Smart ... "The residential security market ...
(Date:10/10/2017)... ... 2017 , ... The Pittcon Program Committee is pleased to ... who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each award ... conference and exposition for laboratory science, which will be held February 26-March 1, ...
Breaking Biology Technology: